Sales begin for first FDA-approved CBD drug

Sales are underway for the first CBD drug approved by the U.S. Food and Drug Administration.

The drug, Epidiolex, treats two rare types of epilepsy and is made from marijuana plants grown in the United Kingdom.

The maker of the medication, GW Pharmaceuticals, has said the tincture would cost about $32,500 a year.

U.S. insurance companies have not yet determined whether they’ll cover the medication, though GW Pharmaceuticals has announced it will cover some costs for potential patients who apply to the company.

Epidiolex was approved by the FDA in June, though sales could not begin until the U.S. Drug Enforcement Administration removed legal restrictions around selling it.

The DEA decided in September that cannabinoid drugs approved by the FDA and containing no more than 0.1% THC would be classified as Schedule 5 drugs, rather than Schedule 1 drugs.

The change was the first time nonsynthetic cannabis has been cleared for medical use by the U.S. government.

GW Pharmaceuticals trades on the Nasdaq as GWPH.

Subscribe to our Newsletter

2 comments on “Sales begin for first FDA-approved CBD drug
  1. Ray on

    How does this make America Great Again?

    GWPH is a British company not an American company. So once again American dollars go overseas while American farmers miss out on a crop, sick Americans who can’t afford $32,000 a year miss out on medication that works, and American cops (who we are told to admire and respect) continue to incarcerate people who choose to medicate with a plant recently approved by the FDA to stop seizures in children.

    Makes me wonder who the DEA, FDA, President, Attorney General, Congress, Senate and DOJ really work for. Sounds like big pharma to me.

    Reply

Leave a Reply

Your email address will not be published. Required fields are marked *